GRAIL Inc (NASDAQ: GRAL, if publicly traded)* is a biotechnology company developing multi-cancer early detection tests using liquid biopsy and next-gen sequencing. Its flagship product, Galleri®, screens for over 50 cancers from a single blood draw. Backed by Illumina and other healthcare giants, GRAIL represents a bold push toward population-wide cancer screening and earlier intervention. *(Note: GRAIL is currently part of Illumina; listing status subject to change.)